


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華控康泰集團有限公司

Kontafarma China Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

INSIDE INFORMATION

UPDATE ON WINDING UP PETITION AGAINST A NON-WHOLLY OWNED SUBSIDIARY OF THE COMPANY

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Kontafarma China Holdings Limited (the “**Company**”) pursuant to Rule 13.09 and Rule 13.25 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 30 April 2024 (the “**30 April 2024 Announcement**”) regarding the winding-up petition (the “**2024 Cayman Petition**”) presented to the Grand Court of the Cayman Islands (the “**Cayman Court**”) by Active Gains Universal Limited (as petitioner), being a shareholder holding 27% shareholding in TFKT True Holdings (“**True Cayman**”) for, amongst others, the winding up of True Cayman, which is a non-wholly owned subsidiary indirectly owned by the Company through Fester Global Limited (“**Fester Global**”). Unless otherwise defined in this announcement, capitalized terms used in this announcement shall have the same meanings as those defined in the 30 April 2024 Announcement.

The Company would like to provide updated information to the shareholders of the Company that on 5 October 2024, the Group received a judgment handed down by the Cayman Court on 3 October 2024 (the “**Cayman Judgment**”) in respect of an application made by Fester Global to strike out or dismiss the 2024 Cayman Petition, or in the alternative to impose a stay of the 2024 Cayman Petition pending determination of the 2019 HK Legal Proceedings and the 2021 HK Legal Proceedings (as respectively mentioned in the 30 April 2024 Announcement) (collectively, the “**Hong Kong Proceedings**”). Under the Cayman Judgment, the Cayman Court granted a temporary case management stay of the 2024 Cayman Petition pending the determination of the Hong Kong Proceedings.

Up to the date of this announcement, the 2019 HK Legal Proceedings and 2021 HK Legal Proceedings, which shall be tried before the same judge and be heard at the same time or immediately after another as the trial judge may direct, are currently at the discovery stage and have not been set down for trial. The Company will continue to monitor the development of the abovementioned legal proceedings and will make further announcement(s) to keep its shareholders and investors informed of any material development as and when appropriate.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board of
Kontafarma China Holdings Limited
Wang Feifei
Chairman

Hong Kong, 7 October 2024

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Wang Feifei (Chairman and President), Ms. Qiao Linna, Ms. Guo Zixiu (Financial Controller) and Mr. Liu Jiankun; one non-executive Director, namely Mr. Huang Yu; and three independent non-executive Directors, namely Dr. Tang Lai Wah, Dr. Ho Ho Ming and Mr. Yao Xiaomin.